Legend Biotech Corp (LEGN)
19.72
+1.13%
Legend Biotech Corp (LEGN) is currently trading at $19.72. This represents a gain of 1.13% from the previous session. With a market capitalization of $3.64B, LEGN is a key component of the Health Care sector. Investors looking to trade LEGN should compare margin rates and options platforms to optimize their portfolio management.
Broker Promotion
Claim Your $300 Cash Bonus →
T&Cs Apply. Trade LEGN commission-free.
Trading Platform Comparison
Moomoo
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Good for small traders
IBKR
- Min Deposit: $0
- Commissions: $0–$0.005/share
- Fractional Shares: ✅
- Options: ✅
- Notes: Professional-level tools
Ameritrade
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Strong research tools
Webull
- Min Deposit: $0
- Commissions: $0
- Fractional Shares: ✅
- Options: ✅
- Notes: Easy mobile app
AI Market Sentiment
As of today, Legend Biotech Corp (LEGN) shows a bullish trend. Analysts are watching the 20.27 level closely.
Fundamentals
Mkt Cap3.64B
P/E Ratio0.0000
Volume1,460,965
60-Day Technical Chart
Advanced Charting
Need more indicators for LEGN? Use the world's #1 platform.
Open LEGN on TradingView →Charting Platforms
TradingView
Advanced charts & indicators, web & mobile
StockCharts
Technical analysis charts with overlays & indicators
BarCharts
Market data, charts, and technical signals
Finviz
Visual stock charts & heatmaps
Yahoo Finance Charts
Basic interactive charts with indicators
Side-by-Side: Stocks Near $20
| Metric |
LEGN +1.13% |
SOFI +3.38% |
BMNR +10.65% |
HPQ +0.05% |
|---|---|---|---|---|
| Price | $19.72 | $19.29 | $21.51 | $18.21 |
| Mkt Cap | $3.64B | $24.60B | $9.78B | $16.72B |
| - | View → | View → | View → |
Latest Headlines
Legend Biotech (LEGN) stock slips in premarket after 9% surge as Gilead-Arcellx deal spotlights Carvykti rivals
TechStock² • Feb 24, 2026
Legend Biotech Corporation (LEGN) is an Outperform on Multiple Myeloma Treatment CARVYKTI Prospects
Yahoo Finance • Dec 11, 2025
Legend Biotech (LEGN): UBS Lowers Price Target to $48, Maintains Buy Rating | LEGN Stock News
GuruFocus • Dec 8, 2025
Single-infusion myeloma therapy linked to longer treatment-free time
Stock Titan • Jan 21, 2026
Legend Biotech Corporation (LEGN) Stock Analysis: A Promising 127.75% Potential Upside in the CAR-T Therapy Sector
DirectorsTalk Interviews • Sep 22, 2025
● Gemini Agentic AI Analyst Insight for LEGN
Market Education
- Trump’s New Tariffs Could Push Up Kitchen Renovation Costs Sep 26, 2025
- Long Short Strategy to Manage Risk May 31, 2024
- Making Sense of Money: How Interest Rates, Bonds, and Stocks Affect Your Wallet Feb 21, 2024
External Research